These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 4851632)

  • 1. Effect of diphenylhydantoin on hepatic drug hydroxylation.
    Petruch F; Schüppel RV; Steinhilber G
    Eur J Clin Pharmacol; 1974 Jul; 7(4):281-5. PubMed ID: 4851632
    [No Abstract]   [Full Text] [Related]  

  • 2. [Effects of anticonvulsive treatment on drug elimination in man. Induction of liver hydroxylating enzyme system by diphenylhydantoin and carbamazepine].
    Petruch F; Schüppel RV
    Bibl Psychiatr; 1975; (151):76-81. PubMed ID: 1156351
    [No Abstract]   [Full Text] [Related]  

  • 3. [Enhanced drug hydroxylation in man under diphenyl-hydantoin therapy].
    Petruch F; Schüppel RV
    Arzneimittelforschung; 1974 Jul; 24(7):1023-5. PubMed ID: 4211429
    [No Abstract]   [Full Text] [Related]  

  • 4. Effect of diphenylhydantoin on cortisol kinetics in humans.
    Choi Y; Thrasher K; Werk EE; Sholiton LJ; Olinger C
    J Pharmacol Exp Ther; 1971 Jan; 176(1):27-34. PubMed ID: 4936459
    [No Abstract]   [Full Text] [Related]  

  • 5. Abnormalities in liver function tests during long-term diphenylhydantoin therapy in epileptic out-patients.
    Andreasen PB; Lyngbye J; Trolle E
    Acta Med Scand; 1973 Oct; 194(4):261-4. PubMed ID: 4749163
    [No Abstract]   [Full Text] [Related]  

  • 6. The influence of diphenylhydantoin on primidone metabolism.
    Fincham RW; Schottelius DD; Sahs AL
    Arch Neurol; 1974 Mar; 30(3):259-62. PubMed ID: 4812960
    [No Abstract]   [Full Text] [Related]  

  • 7. Impairment of hepatic drug metabolism in patients with acute viral hepatitis.
    Narang AP; Datta DV; Nath N; Mathur VS
    Eur J Drug Metab Pharmacokinet; 1982; 7(4):255-8. PubMed ID: 7166177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urinary D-glucaric acid excretion and acetanilide pharmacokinetics before and during diphenylhydantoin administration.
    Cunningham JL; Evans DA
    Eur J Clin Pharmacol; 1974 Aug; 7(5):387-91. PubMed ID: 4417891
    [No Abstract]   [Full Text] [Related]  

  • 9. Editorial: Drug metabolism in disease.
    Lancet; 1974 Apr; 1(7861):790-1. PubMed ID: 4132718
    [No Abstract]   [Full Text] [Related]  

  • 10. Alteration of hepatic drug metabolism in female patients with congestive cardiac failure.
    Rissam HS; Nair CR; Anand IS; Madappa C; Wahi PL
    Int J Clin Pharmacol Ther Toxicol; 1983 Dec; 21(12):602-4. PubMed ID: 6668098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiopyrine half-life as a measure of hepatic enzyme induction: clinical applications in a chronic epileptic population.
    Byrne E; Harman AW; Frewin DB; Hallpike JF
    Clin Exp Neurol; 1979; 16():183-9. PubMed ID: 550940
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of drug metabolism by hydroxylated metabolites: cross-inhibition and specificity.
    Soda DM; Levy G
    J Pharm Sci; 1975 Dec; 64(12):1928-31. PubMed ID: 1206483
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatic drug metabolism after phenobarbital and diphenylhydantoin administration in the rat--influence of vitamin D3 status.
    Gascon-Barré M; Côte MG; Brodeur J
    Biochem Pharmacol; 1979; 28(2):313-9. PubMed ID: 218591
    [No Abstract]   [Full Text] [Related]  

  • 14. Hepatic drug metabolizing capacity of patients of cirrhosis before and after clinico-biochemical recovery.
    Chauhan CK; Nanivadekar SA; Billimoria FR
    Indian J Physiol Pharmacol; 1989; 33(1):63-6. PubMed ID: 2737749
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interindividual differences in rates of drug oxidation in man.
    Davies DS; Thorgeirsson SS; Breckenridge A; Orme M
    Drug Metab Dispos; 1973; 1(1):411-7. PubMed ID: 4149412
    [No Abstract]   [Full Text] [Related]  

  • 16. One daily dose of diphenylhydantoin (DPH) to patients with epilepsy.
    Strandjord RE; Johannessen SI
    Acta Neurol Scand Suppl; 1972; 51():499-500. PubMed ID: 4514392
    [No Abstract]   [Full Text] [Related]  

  • 17. Diphenylhydantoin stimulation of various pathways of hepatic microsomal drug metabolism in rabbits.
    Gut I; Becker BA
    Acta Univ Carol Med (Praha); 1980; 26(1-2):105-14. PubMed ID: 7315667
    [No Abstract]   [Full Text] [Related]  

  • 18. [Studies of the effect of 5,5-diphenylhydantoin on the bioelectric activity of the brain in epilepsy].
    Domzal T; Gajkowski K
    Neurol Neurochir Pol; 1971; 5(3):301-6. PubMed ID: 5000628
    [No Abstract]   [Full Text] [Related]  

  • 19. Inhibition of diphenylhydantoin elimination by its major metabolite.
    Ashley JJ; Levy G
    Res Commun Chem Pathol Pharmacol; 1972 Sep; 4(2):297-306. PubMed ID: 5074529
    [No Abstract]   [Full Text] [Related]  

  • 20. Measurement of hepatic drug-metabolizing enxyme activity in man. Comparison of three different assays.
    Sotaniemi EA; Pelkonen RO; Puukka M
    Eur J Clin Pharmacol; 1980 Apr; 17(4):267-74. PubMed ID: 6105079
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.